With the introduction of anti-TNF-therapies in the treatment algorithm of inflammatory bowel diseases (IBD) over two decades ago, the era of biologics began and treatment options are still expanding [1–6] with an armamentarium of biologics and small molecules for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). The gene discussed is TNF; the disease is inflammatory bowel disease.